Resumo

GOICOCHEA, María Teresa  e  BONAMICO, Lucas. Migraine preventive treatment: monoclonal antibodies against calcitonine gene related peptide. Medicina (B. Aires) [online]. 2021, vol.81, n.3, pp.427-431. ISSN 0025-7680.

Migraine is a very prevalent disorder that is estimated to affect about 10-15% of adult subjects. Ac cording to the World Health Organization migraine is one of the first causes of disability. Traditional preventive treatments discovered by serendipity include Beta blockers, antinconvulsants drugs, calcium channel blockers, tricyclic antidepressants and onabotulinum A and offer about 50% efficacy after controlled placebo trials and real life use. Because of lack of adherence and adverse events, there is a loss of beneficial sustain on these treat ments. Recently, the efficacy and safety of monoclonal antibodies (MA) that act on the peptide pathway related to the calcitonin gene (CGRP) has been evaluated in migraine, being the first specific tailored treatment on one of the multiple targets on migraine. This family of drugs: erenumab, galcanezumab, fremanezumab, eptinezumab, finished Fase III, extensions trials and many of them are in the market approved since 2018.Since 2019 are available in Argentina. We will describe the rationale for the prescription of this family of new drugs for migraine.

Palavras-chave : Migraine; Monoclonal antibodies; Peptide related to the calcitonin gene; Preventive treatment.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )